Shrikant Tamhane, MD
Endocrinology, Diabetes & Metabolism · Columbus, OHNPI 1891040762
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (39.9%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Neurocrine Biosciences, Inc. accounts for 67.1% of it on its own, with 37 other manufacturers making up the rest. 2025 is the largest year on record at $44,401, more than ten times the $3,299 reported in 2019. Among endocrinology, diabetes & metabolism clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 599 payments — averaging $91.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$37K
- Amgen$9K
- Boehringer Ingelheim$2K
- Lilly USA, LLC$808
- Novo Nordisk$751
- AstraZeneca$724
- plus $5K from 32 others
What the payments were for
- Consulting fees$18,60034%
- Speaking & faculty fees$21,90040%
- Travel & lodging$4,2418%
- Food & beverage$9,97218%
- Education$1380%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 32 | $36,820 |
| Amgen(2 entities) | 84 | $9,152 |
| Boehringer Ingelheim | 42 | $1,760 |
| Lilly USA, LLC | 42 | $808 |
| Novo Nordisk | 55 | $751 |
| AstraZeneca(2 entities) | 39 | $724 |
| Abbott | 32 | $642 |
| Sanofi-aventis U.S. LLC | 42 | $589 |
| Corcept Therapeutics | 34 | $516 |
| Xeris Pharmaceuticals, Inc. | 17 | $325 |
| Insulet Corporation | 8 | $315 |
| Dexcom, Inc. | 17 | $295 |
| Bayer | 17 | $294 |
| Medtronic(2 entities) | 13 | $223 |
| Tandem Diabetes Care, Inc. | 11 | $196 |
| Valeritas, Inc. | 39 | $182 |
| Kyowa Kirin, Inc. | 7 | $178 |
| Mannkind Corporation | 10 | $161 |
| Merck | 8 | $130 |
| Amarin Pharma, Inc. | 8 | $129 |
| Radius Health, Inc. | 6 | $126 |
| Shire North American Group Inc | 6 | $100 |
| IBSA Pharma Inc. | 4 | $65 |
| AbbVie | 4 | $56 |
| Amryt Pharma Holdings Ltd | 3 | $46 |
| Jazz Pharmaceuticals Inc. | 3 | $38 |
| Johnson & Johnson | 3 | $38 |
| Currax Pharmaceuticals LLC | 2 | $25 |
| Vivus LLC | 1 | $24 |
| Lifescan, Inc. | 2 | $23 |
| BETA Bionics, Inc. | 1 | $18 |
| Senseonics, Incorporated | 1 | $16 |
| Nevro Corp. | 1 | $16 |
| Sequel Med Tech, LLC | 1 | $15 |
| Eisai Inc. | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Ultragenyx Pharmaceutical Inc. | 1 | $13 |
| Companion Medical, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CRENESSITY$34,671
- EVENITY$7,961
- JARDIANCE$1,217
- Omnipod$123
How this compares
$54,852 in reported general payments places this provider in the 90th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.
See all endocrinology, diabetes & metabolism providers in Ohio →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 228 | $236,106 |
| MounjaroTirzepatide | 83 | $89,937 |
| JardianceEmpagliflozin | 57 | $43,363 |
| TrulicityDulaglutide | 38 | $37,655 |
| Tresiba Flextouch U-100Insulin Degludec | 68 | $37,107 |
| FarxigaDapagliflozin Propanediol | 46 | $32,434 |
| Tresiba Flextouch U-200Insulin Degludec | 28 | $27,409 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 29 | $15,643 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 35 | $14,245 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 21 | $13,764 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 25 | $10,615 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 20 | $9,520 |
| TradjentaLinagliptin | 22 | $8,026 |
| FiaspInsulin Aspart (Niacinamide) | 23 | $7,651 |
| Novolog FlexpenInsulin Aspart | 43 | $7,445 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Fiasp, Novolog | $751 | $246,952268 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $808 | $130,848145 claims |
| Boehringer IngelheimJardiance, Tradjenta | $1,760 | $51,39079 claims |
| AstraZenecaFarxiga | $724 | $32,43446 claims |
| Sanofi-aventis U.S. LLCLantus | $589 | $1,09616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.
Other endocrinology, diabetes & metabolism in Columbus
- Elena ChristofidesColumbus$2.3M
- Samuel AndersonColumbus$556K
- Ravi DhawaleColumbus$175K
- Laura RyanColumbus$126K
- Kathleen WyneColumbus$88K
- Kathleen DunganColumbus$60K
- Jay PatelColumbus$60K
- Lawrence KirschnerColumbus$57K
- Constantine KroustosColumbus$53K
- Laura ButzColumbus$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.